Zion Market Research has published a new report titled “Antifungal Drug Market by Drug Type (Echinocandins, Azoles, Ployenes, Allylamines, and Others), by Dosage Form (Powders, Ointments, Drugs and Pastes), and by Therapeutic Indication (Aspergillosis, Dermatophytosis, Candidiasis and Others) – Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2026.” According to the report, the Antifungal Drug Market accounted for USD 13.14 Billion in 2019 and is expected to reach USD 16.83 Billion by 2026, growing at a CAGR of around 3.6% between 2020 and 2026.
Get Free Sample Of Report – https://www.zionmarketresearch.com/sample/antifungal-drug-market
Compromised immune system and torpid lifestyle to power the global antifungal drug market in the forecast period
The antifungal drug market is mainly boosted by rising prevalence of fungal infection all over the world, as per analysts at Zion Market Research. In addition to this, rising awareness is a primary factor that is likely to market the development of antifungal drug market. Furthermore, the compromised immune system and torpid lifestyle can impact the antifungal drug market. On the other hand, huge penetration of conservative medication paired with the conventional approach of therapy is the major limiting for the development of antifungal drug market.
Nevertheless, in-progress R&D in developing anti-fungal drugs is expected to bring growth opportunities in the future for the antifungal drug market. For instance, in August 2018, a research was conducted by the scientists that proved azole antifungals restrain the pathway for fungal ergosterol biosynthesis. This leads to either killing of the pathogen or increasing inhibition relying on the species.
Speedy spread of fungal infection to maintain the dominance of asia pacific in antifungal drug market in years to come
In terms of topography, North America was the top area for antifungal drug market in terms of income in 2019. This development is supported by broad awareness related to fungi associated infection. North America added up for almost over USD 4.20 Billion in 2019 which is almost over 35% of world total for antifungal drug market. In addition to this, lifestyle-associated factors such as torpid sedentary lifestyle have turned out to be very common in European nations and the U.S., which result in weakening the immune system and thus pace the fungal infections, boosting the antifungal drug market. Asia Pacific is likely to be the quickest area for the antifungal drug market in the years to come due to the speedy spread of fungal infection in this area.
On the basis of the dosage form, the global antifungal drug market is divided into 4 types such as ointments, powders, pastes, and drugs. Ointment and powder dosage form ruled the antifungal drug market in 2019. The development is credited due to easy accessibility of antifungal drug products in the medical shops.
The key players operating in the global antifungal drug market are Asperqillus, Alternaria, Abbott Laboratories, Pfizer, Glaxosmithkline, Bayer Healthcare, Novartis, Sanofi-Aventis, Merck & Co., Kramer Laboratories, Enzon Pharmaceuticals, and Gilead.
The global antifungal drug market is segmented as follows:
To view TOC of this report – https://www.zionmarketresearch.com/toc/antifungal-drug-market